Baxter Announces Strategic Actions to Enhance Operational …
WEBJan 6, 2023 · Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders.
Baxter Newsroom
WEBWe invite you to read the latest news about our initiatives and innovations, and follow us on our corporate social media channels to receive timely updates.
Baxter - Baxter to Acquire Hillrom, Expanding Connected Care and ...
WEBSep 2, 2021 · Builds on Baxter’s global footprint to expand Hillrom’s penetration of international markets; Creates significant opportunities to position Baxter for faster top- and bottom-line growth; Expected to generate high single-digit ROIC by year five
Baxter Announces Definitive Agreement to Divest Its Vantive …
WEBAug 13, 2024 · Baxter International Inc. (NYSE:BAX), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ:CG) today announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion.
Baxter Signs Definitive Agreement to Divest its BioPharma …
WEBMay 8, 2023 · Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth ...
Baxter Reports Second-Quarter 2023 Results
WEBJul 27, 2023 · Second-quarter performance was partially offset by a low single-digit decline in Patient Support Systems, primarily resulting from lower rental revenues, as well as lower sales in BPS (reported in discontinued operations) due to a reduction in COVID vaccine manufacturing revenues.
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
WEBFeb 8, 2024 · Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
Baxter Reports First-Quarter 2024 Results
WEBMay 2, 2024 · Baxter Reports First-Quarter 2024 Results. First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance 1.
Investors - Events & News - Baxter
WEBInformation regarding Baxter’s recent announcements, upcoming & past events, and other useful resources for investors. Annual Reports & Proxy. Baxter's Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year. Financial Schedules. Financial schedules and Non-GAAP reconciliations by quarter. SEC Filings
Baxter - Baxter Highlights Business Strategies and Innovation at …
WEBMay 25, 2022 · Baxter expects constant currency sales growth of 4% to 5% on a compounded annual basis from 2022 through 2025. The company expects 2025 adjusted operating margin to expand by 350 to 400 basis points as compared to expected year-end 2022. Baxter anticipates free cash flow conversion of more than 80% by 2025.